Trending menu:
News
-
22 August 2019
Oxurion reports mixed results from Phase IIa DME study
Oxurion has reported top-line results from the Phase IIa clinical trial of THR-317 in combination with ranibizumab to treat diabetic macular edema (DME) patients.
-
22 August 2019
ViiV’s long-acting HIV regimen passes late-stage trial
ViiV Healthcare has reported that the Phase III ATLAS-2M clinical trial of its long-acting, two-drug regimen developed to treat HIV infection met its primary endpoint.
-
21 August 2019
Fulcrum launches Phase IIb trial of losmapimod to treat FSHD
Fulcrum Therapeutics has started a Phase IIb clinical trial of losmapimod in patients suffering from facioscapulohumeral muscular dystrophy (FSHD).
-
21 August 2019
Synlogic terminates development of ammonia lowering drug
Synlogic has announced plans to suspend the clinical development of SYNB1020 following negative results from the candidate’s Phase Ib/IIa clinical trial in hyperammonemia patients.
-
21 August 2019
Group K Diagnostics and Health Network agree to start clinical trials
Biotechnology firm Group K Diagnostics (GKD) and laboratory medicine services provider Health Network Laboratories (HNL) have partnered on a clinical trial agreement to bring improved clinical experiences to patients and...
-
21 August 2019
Outlook Therapeutics closes enrolment in Phase III wet AMD study
Outlook Therapeutics has concluded the enrolment of patients in a Phase III clinical trial of ONS-5010 for the treatment of patients with wet age-related macular degeneration (wet AMD).
-
20 August 2019
Knopp begins study of dexpramipexole in eosinophilic asthma patients
Knopp Biosciences has commenced patient enrolment in a Phase II clinical trial of dexpramipexole for the treatment of moderate-to-severe eosinophilic asthma.
-
20 August 2019
Abivax starts enrolment in Phase IIb ulcerative colitis study
Abivax has recruited the first patient for a Phase IIb clinical trial assessing oral, once-daily ABX464 to treat moderate to severe active ulcerative colitis (UC).
-
20 August 2019
VirTrial and ACRP partner on hybrid decentralised clinical trials
Technology company VirTrial has partnered with the Association of Clinical Research Professionals (ACRP) to provide a training and certificate programme to all domestic and abroad members of ACRP.
-
20 August 2019
Farxiga meets primary goal in Phase III heart failure trial
AstraZeneca’s Farxiga (dapagliflozin) has met the primary endpoint in Phase III DAPA-HF study involving patients with reduced ejection fraction (HFrEF), with or without type 2 diabetes.